title: Comparison of the acute hemodynamic effects of hypertonic or colloid infusions immediately after mitral valve repair.
abstract: OBJECTIVE
  To determine the acute hemodynamic effect of hypertonic saline and/or colloid solutions as volume resuscitation in postoperative mitral valve repair patients.
  
  
  METHODS
  Prospective, randomized trial.
  
  
  METHODS
  Postoperative cardiac intensive care unit of Broussais Hospital.
  
  
  METHODS
  Twenty-six patients who underwent mitral valve repair were prospectively studied. Two patients were excluded during the study.
  
  
  METHODS
  During the immediate postoperative period, when wedge pressure decreases to <8 mm Hg, patients were randomly assigned to receive 250 mL of either hypertonic saline 7.2%-hydroxyethyl starch 6% (molecular weight, 200,000; hydroxyethylation ratio, 0.5) solution (HS-HES group), hypertonic saline 7.2% solution (HS group), or hydroxyethyl starch 6% solution (HES group). The infusion was completed within 15 mins. No additional volume was infused throughout the study.
  
  
  RESULTS
  Standard hemodynamic measurements and echocardiographic data demonstrated that HS-HES and HS induced a higher increase in left ventricular end-diastolic area than HES. In the HS-HES and HS groups, systemic vascular resistances decreased significantly and end-systolic area tended to decrease. In the HES group, systemic vascular resistances did not change and end-systolic area tended to increase. Accordingly, ejection fraction increased significantly by 21% and 18% with HS-HES (from 50.5 +/- 5.5 to 61.2 +/- 4.8) and HS (from 49.7 +/- 3.6 to 58.8 +/- 3.3), respectively, and did not change with HES. A major increase in cardiac index was observed after hypertonic solutions infusion, from 2.9 +/- 0.3 to 4.1 +/- 0.4 L/min/m2 in the HS-HES group and from 2.7 +/- 0.3 to 3.8 +/- 0.4 L/min/m2 in the HS group. Then, cardiac index progressively returned to baseline values within the 3 hrs after the infusion. No significant difference was observed between HS-HES and HS. In these groups, plasma sodium increased significantly after the infusion and remained higher than baseline values throughout the study. Adverse events were observed only with hypertonic solution administration: hypotensive episodes, sudden increases in pulmonary capillary wedge pressure, and ventricular arrhythmias. These side effects are likely attributable to a too-high dose and/or rate of infusion. All patients included in the study were discharged from the hospital before the 10th postoperative day.
  
  
  CONCLUSIONS
  We conclude that in patients who have undergone mitral valve repair, postoperative infusion of hypertonic saline solutions increases left ventricular preload and left ventricular ejection fraction. The use of these hypertonic solutions may be of interest in patients with valvular cardiomyopathy. A titrated dose and a low rate of infusion may substantially improve the safety.
authors.affiliation: Department of Anesthesiology, Broussais Hospital, Paris, France. jfbaron.broussais@invivo.edu
authors.forename: D
authors.initials: D
authors.lastname: Sirieix
authors.forename: J M
authors.initials: JM
authors.lastname: Hongnat
authors.forename: S
authors.initials: S
authors.lastname: Delayance
authors.forename: N
authors.initials: N
authors.lastname: D'Attellis
authors.forename: E
authors.initials: E
authors.lastname: Vicaut
authors.forename: A
authors.initials: A
authors.lastname: Bérrébi
authors.forename: M
authors.initials: M
authors.lastname: Paris
authors.forename: J N
authors.initials: JN
authors.lastname: Fabiani
authors.forename: A
authors.initials: A
authors.lastname: Carpentier
authors.forename: J F
authors.initials: JF
authors.lastname: Baron
mesh_terms: D006348:Cardiac Surgical Procedures; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003102:Colloids; D003325:Coronary Care Units; D017548:Echocardiography, Transesophageal; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery*; D010952:Plasma Substitutes / Q000008:administration & dosage*; D011182:Postoperative Care / Q000379:methods; D011446:Prospective Studies; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D003102:Colloids; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D012462:Saline Solution, Hypertonic